0.7138
price up icon6.95%   0.0464
after-market Handel nachbörslich: .70 -0.0138 -1.93%
loading
Schlusskurs vom Vortag:
$0.6674
Offen:
$0.6933
24-Stunden-Volumen:
1.66M
Relative Volume:
0.24
Marktkapitalisierung:
$44.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.83M
KGV:
-0.9035
EPS:
-0.79
Netto-Cashflow:
$-20.87M
1W Leistung:
-0.18%
1M Leistung:
+76.25%
6M Leistung:
+13.66%
1J Leistung:
-2.03%
1-Tages-Spanne:
Value
$0.6729
$0.7278
1-Wochen-Bereich:
Value
$0.5555
$0.75
52-Wochen-Spanne:
Value
$0.2223
$1.29

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name
Firmenname
Cognition Therapeutics Inc
Name
Telefon
412-481-2210
Name
Adresse
2403 SIDNEY STREET, PITTSBURGH
Name
Mitarbeiter
25
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-08
Name
Neueste SEC-Einreichungen
Name
CGTX's Discussions on Twitter

Vergleichen Sie CGTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CGTX
Cognition Therapeutics Inc
0.7138 41.37M 0 -22.83M -20.87M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 118.67B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.54 59.23B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
419.56 52.67B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
690.32 41.24B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
304.30 32.36B 3.81B -644.79M -669.77M -6.24

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-19 Hochstufung B. Riley Securities Neutral → Buy
2024-07-30 Herabstufung Cantor Fitzgerald Overweight → Neutral
2021-11-03 Eingeleitet B. Riley Securities Buy
2021-11-03 Eingeleitet Oppenheimer Outperform

Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten

pulisher
Aug 03, 2025

Is Cognition Therapeutics Inc. a good long term investmentCapitalize on momentum-driven stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Cognition Therapeutics Inc.Invest confidently with real-time updates - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What catalysts could drive Cognition Therapeutics Inc. stock higher in 2025Superior profit margins - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What makes Cognition Therapeutics Inc. stock price move sharplyMaximize returns with disciplined trading approaches - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Cognition Therapeutics Inc. stockTriple-digit returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionFree Daily Trading Room Entry - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

How volatile is Cognition Therapeutics Inc. stock compared to the marketBreakthrough capital growth - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What analysts say about Cognition Therapeutics Inc. stockDynamic growth stocks - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What institutional investors are buying Cognition Therapeutics Inc. stockAchieve rapid returns with smart investment plans - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

Does Cognition Therapeutics Inc. stock perform well during market downturnsGet exclusive access to premium stock research - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

Is Cognition Therapeutics Inc. a growth stock or a value stockValue Investing Entry Points With Proven Results - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

What are analysts’ price targets for Cognition Therapeutics Inc. in the next 12 monthsPost Market Recommendation With High Returns - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors - TipRanks

Aug 01, 2025
pulisher
Jul 30, 2025

Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s - Yahoo Finance

Jul 30, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 20:05:06 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Applying sector rotation models to Cognition Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease - Psychiatric Times

Jul 29, 2025
pulisher
Jul 29, 2025

How high can Cognition Therapeutics Inc. stock price go in 2025Conservative Long Term Growth Plans Under Review - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Cognition Therapeutics Presents Data at AAIC Highlighting - GlobeNewswire

Jul 29, 2025
pulisher
Jul 29, 2025

Breakthrough Drug Zervimesine Halts Alzheimer's Decline by 129%, Shows Promise in Lewy Body Dementia - Stock Titan

Jul 29, 2025
pulisher
Jul 29, 2025

Cognition Therapeutics shares rise 3.50% premarket after PTC Therapeutics' FDA approval of Sephience. - AInvest

Jul 29, 2025
pulisher
Jul 25, 2025

What drives Cognition Therapeutics Inc. stock priceExceptional profit velocity - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Cognition Therapeutics Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional

Jul 25, 2025
pulisher
Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire

Jul 21, 2025
pulisher
Jul 21, 2025

Cognition Therapeutics reports positive results for Alzheimer’s drug By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times

Jul 21, 2025

Finanzdaten der Cognition Therapeutics Inc-Aktie (CGTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$78.04
price up icon 3.24%
$37.88
price up icon 2.07%
$111.24
price up icon 2.35%
$29.32
price up icon 8.31%
$110.03
price up icon 2.51%
biotechnology ONC
$304.30
price up icon 1.77%
Kapitalisierung:     |  Volumen (24h):